Longitudinal analysis over 2 and 6 years found greater deterioration in scales of depression, RBD, olfaction, global cognition as well as the Unified Parkinson’s Disease Rating Scale (UPDRS) part II and III scores in the GBA1NMC group compared to healthy controls without GBA1 mutation (GBA1wildtype)12–14. The gene discussed is GBA1; the disease is depressive symptom measurement.